How long does it take gout medicine to work?

Gout medicine works on two very different timescales depending on what it is trying to do. Drugs that treat an acute flare can begin relieving pain within hours, while drugs that lower uric acid levels and prevent future attacks take weeks to months before their benefits become apparent. Colchicine, for instance, shows measurable pain relief within about 16 hours of dosing, whereas allopurinol and similar urate-lowering drugs need gradual dose increases over several weeks and may not prevent flares for six months or longer. Understanding which timeline applies to which drug is the key to setting realistic expectations.

How Quickly Acute Flare Treatments Relieve Pain

When a gout flare hits, the goal is simple: get the inflammation and pain under control as fast as possible. Three main categories of drugs are used for this, and they each work on a slightly different schedule.

Colchicine is one of the oldest gout treatments still in use. A multicenter trial found that low-dose colchicine produced at least a 50% reduction in pain within 24 hours in about 38% of patients, compared with roughly 16% given a placebo.¹ A separate analysis of the same trial data concluded that significant pain relief was detectable as soon as 16 hours after dosing, making colchicine one of the faster-acting oral options.² Colchicine works best when taken early, ideally within the first 12 to 24 hours of a flare. The longer you wait, the less effective it tends to be.

NSAIDs such as naproxen and indomethacin are the other common first-line choice. A Cochrane review found that more participants reached a 50% pain reduction at 24 hours with NSAIDs than with placebo, though the evidence base was limited.³ That said, the same analysis noted that statistically significant pain reduction in NSAID trials has typically been demonstrated at around 48 hours, so full relief often takes a couple of days rather than overnight.²

Corticosteroids, whether oral prednisone or an injection directly into the joint, generally start working within a day or two. They are especially useful when someone cannot tolerate NSAIDs or colchicine because of kidney problems, stomach issues, or drug interactions. Joint injections tend to bring faster, more localized relief than oral steroids.

For people who cannot use any of the above, biologic drugs targeting interleukin-1, such as anakinra and canakinumab, are sometimes used. A case series and literature review found that the vast majority of flares treated with anakinra responded partially or completely within one to three days.⁴ These drugs are reserved for difficult cases because they are expensive and carry infection risks, but they work on a similar one-to-three-day timeline as the more standard options.

How Long a Full Flare Takes to Resolve

Bringing pain down by half is not the same as making a flare disappear. Even with prompt treatment, most acute gout flares take several days to fully resolve. A randomized trial measuring time to complete resolution found a median of about six days, with clinical resolution (meaning the joint felt mostly normal) occurring at roughly four days.⁵ That is with treatment. Without any medication, a gout flare can last one to two weeks or occasionally longer before the immune response runs its course on its own.

The practical takeaway is that acute gout drugs start reducing pain within the first day or two, but you should expect some lingering discomfort for the better part of a week. If a flare is not improving at all after 48 hours, that is worth a call to your doctor, because it may mean the drug needs to be switched or a different diagnosis should be considered.

Urate-Lowering Therapy and the Slow Road to Prevention

Acute treatments put out fires. Urate-lowering therapy (ULT) is meant to stop fires from starting. Drugs like allopurinol, febuxostat, and probenecid work by reducing the amount of uric acid circulating in your blood, which over time allows the urate crystals deposited in your joints to dissolve. This process is not fast.

Allopurinol, by far the most commonly prescribed ULT worldwide, is typically started at a low dose and increased gradually every few weeks until blood uric acid drops below a target level, usually 6 mg/dL or lower. A study of dose escalation found that the average drop in serum urate from month 12 to month 24 was about 1.1 mg/dL in the group whose dose was being escalated, confirming that reaching the target can take many months of careful adjustment.⁶ For people with kidney disease, the starting dose is often even lower, around 50 mg per day, and increases are more gradual, which stretches the timeline further.⁷

Febuxostat works by the same general mechanism as allopurinol, blocking the enzyme that produces uric acid, and tends to lower urate more effectively at standard doses. A head-to-head trial showed that febuxostat at 80 mg or 120 mg daily was more effective than allopurinol at a fixed 300 mg daily dose in bringing uric acid levels down.⁸ But “more effective” does not mean “faster” in a practical sense. Febuxostat still needs weeks of treatment to reach steady state, and the crystal dissolution process downstream remains slow regardless of how quickly serum uric acid drops.

Pegloticase occupies a completely different niche. It is an intravenous enzyme that directly breaks down uric acid in the blood, and its speed is dramatic: a phase II trial showed that plasma urate fell to 6 mg/dL or below within six hours of a single infusion.⁹ Randomized controlled trials confirmed that uric acid normalized within 24 hours of the first dose in all patients who received it, though some lost that response over time while others maintained it throughout the treatment period.¹⁰ Pegloticase is reserved for people with severe, treatment-refractory gout, the kind that has not responded to anything else, because it requires infusions every two weeks and carries risks including serious allergic reactions.

Why You Might Feel Worse Before You Feel Better

One of the most frustrating aspects of starting urate-lowering therapy is that it can actually trigger more gout flares, at least initially. This is not the drug failing. It is a well-recognized paradox: when uric acid levels drop, crystals that were stable in the joint begin to partially dissolve, exposing fresh crystal surfaces that provoke a new inflammatory response. The risk of these flares is highest in the first several months after starting treatment.¹¹

This is exactly why doctors prescribe a low-dose anti-inflammatory alongside ULT at the start. Guidelines from rheumatology societies in France and elsewhere recommend prophylactic low-dose colchicine (typically 0.5 mg once or twice daily) or low-dose naproxen for at least six months after beginning urate-lowering therapy.¹² ¹³ The six-month window is not arbitrary; it roughly corresponds to the period of highest flare risk while crystal stores are being actively disrupted.

Many people abandon their urate-lowering drug during this phase because it feels counterintuitive, like the treatment is making things worse. Physicians who prescribe these drugs know this, and the best ones explain the paradox upfront. If nobody warns you, the natural instinct is to stop taking the medication. That decision, while understandable, resets the clock and means the crystals never fully dissolve.

How Long Until the Crystals Are Actually Gone

Lowering uric acid in the blood is only the first step. The real goal is dissolving the monosodium urate crystals that have accumulated in joints and soft tissues, sometimes over years or decades. A study that tracked crystal disappearance using joint fluid analysis found that after serum uric acid was brought below normal levels, crystals took anywhere from 3 to 33 months to fully disappear. The time correlated strongly with how long the person had been living with gout: the longer the history, the longer the dissolution.¹⁴

That range tells you something important. If you were diagnosed with gout a year ago and have a modest crystal load, keeping your uric acid consistently below target might clear the crystals within a few months. If you have had gout for 15 years with large tophi, you are looking at a process measured in years. The key variable is consistency: every gap in treatment allows uric acid to rise again, and crystals can re-form remarkably quickly.

Once the crystals are truly gone, flares should stop. This is the point where ULT transitions from “managing a chronic disease” to “maintaining a cure,” though you still need to keep taking the drug to prevent uric acid from climbing back up.

Factors That Speed Up or Slow Down the Timeline

Not everyone responds to gout medication on the same schedule. Several variables shift the timeline in meaningful ways.

Kidney function is the biggest one. The kidneys are responsible for excreting most of the uric acid your body produces, so impaired kidney function makes both the disease and the treatment harder. Colchicine is cleared by the kidneys, and in someone with severe kidney impairment, a standard dose produces roughly double the drug exposure compared to someone with normal kidney function. That means dose reductions are necessary, which can slow the onset of pain relief.¹⁵ On the ULT side, allopurinol in patients with moderate to severe kidney disease is typically started at 50 mg daily instead of the usual 100 mg, with slower dose escalation.⁷ The treatment still works, but reaching the target uric acid level takes longer.

Starting uric acid level and crystal burden also matter. An analysis of trial data found that people who achieved their serum urate target were far less likely to have flares between months 12 and 24 than those who did not: about 27% of responders had a flare in that window, compared with 64% of non-responders.¹⁶ In plain terms, the further your uric acid has to fall and the more crystal you have stored up, the longer and rockier the road.

Having a flare right before starting ULT also predicts trouble early on. A study of patients starting allopurinol using a start-low, go-slow strategy found that a gout flare in the month before beginning treatment more than doubled the odds of having another flare in the first six months.¹⁷ The same study found that starting at 100 mg of allopurinol rather than 50 mg also raised early flare risk, reinforcing the rationale for starting low.

Can You Start Allopurinol During a Flare?

For years, the conventional wisdom was to wait until a gout flare had fully resolved before beginning urate-lowering therapy, out of fear that changing uric acid levels mid-flare would make things worse. That advice has shifted. A randomized trial comparing early allopurinol initiation during a flare with the traditional delayed start found no meaningful difference in pain scores, time to resolution, or overall flare duration between the two groups.⁵ Both groups reached clinical resolution in a median of about four days.

This matters practically because a gout flare is often the moment a person is most motivated to start preventive treatment. If you have to wait two weeks for the flare to pass and then schedule a follow-up visit, the window of motivation closes and many people never start ULT at all. Current guidelines from both the American College of Rheumatology and several European societies now permit starting allopurinol during an acute flare, as long as appropriate anti-inflammatory treatment is also given.

What Happens When People Stop Taking Their Medication

Gout medication only works if you keep taking it. That sounds obvious, but adherence rates for urate-lowering therapy are notoriously poor, worse than for most other chronic conditions. A five-year follow-up study found a stark gap between patients who took their medication consistently and those who did not: only about 45% of people in the lowest adherence group had reached their uric acid target, compared with nearly 88% in the highest adherence group.¹⁸ Flare rates told the same story: about a third of non-adherent patients reported flares in the preceding year, versus fewer than one in ten among the most adherent.

The reasons people stop are varied. Some stop during the early paradoxical-flare period, as discussed above. Others stop because they feel fine between attacks and do not see the point of a daily pill. Still others have side effects they find intolerable, or their doctor never explained that the drug is meant to be taken indefinitely, like a blood pressure medication, not just until the next flare. Whatever the reason, gaps in treatment allow uric acid to creep back up and crystals to re-form, effectively resetting the timeline.

Drug Interactions and Timing Pitfalls

Colchicine has a particularly narrow margin between a dose that works and a dose that causes side effects like diarrhea and nausea. This margin shrinks further if you take certain other medications. Drugs that inhibit a liver enzyme called CYP3A4, including common antibiotics like clarithromycin, antifungals like ketoconazole, and some heart medications like diltiazem, can effectively double your colchicine exposure and turn a safe dose into a dangerous one.¹⁵ If you are on any of these and need colchicine for a flare, your doctor will likely cut the dose in half or choose a different drug entirely. The result is the same: potentially slower relief because the effective dose is lower.

NSAIDs come with their own timing considerations. They are most effective when started as early as possible in a flare, ideally within the first 24 hours. Waiting two or three days before starting an NSAID means the inflammatory cascade has had time to build, and the drug has more work to do. People on blood thinners, certain blood pressure medications, or who have a history of stomach ulcers may need to avoid NSAIDs altogether, which can force a switch to a slower or less convenient option.

For urate-lowering therapy, the interaction landscape is different. Allopurinol increases the toxicity of azathioprine, an immunosuppressant used in organ transplant recipients and autoimmune diseases, and the two should almost never be combined without careful dose adjustment. Febuxostat has fewer of these interactions, which is one reason it is sometimes preferred in patients on complex medication regimens despite its higher cost.

Tophi and the Longest Timeline

Tophi are the chalky nodules that develop under the skin in advanced gout, usually around finger joints, elbows, ears, and the Achilles tendon. They are made of packed urate crystals surrounded by inflammatory tissue, and they represent the far end of the “how long does this take” question. Small tophi may shrink and eventually disappear after a year or two of consistent urate-lowering therapy. Large tophi can take several years to resolve, and some require surgical removal because the drug simply cannot dissolve the mass fast enough.

Pegloticase, with its ability to crash uric acid levels to near zero within hours, can dissolve tophi faster than oral ULT. In clinical trials, visible tophi shrank substantially over six months of biweekly infusions in patients who maintained a uric acid response.¹⁰ But pegloticase is a last resort, not a shortcut. Its cost, infusion requirements, and risk of allergic reactions mean it is only offered after oral therapies have genuinely failed.

Whether you are dealing with a single angry toe joint or years of accumulated crystal deposits, the honest answer to how long gout medicine takes to work is that the acute pain drugs start helping within hours to days, while the long-term preventive drugs ask for months to years of patience. The timeline is frustrating but knowable, and almost everyone who sticks with treatment gets there eventually.

1
PubMed. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study
2
ACR Meeting Abstracts. Colchicine As Assessed by Target Joint Pain Scores Is Effective at 16 Hours in Patients with Acute Gout Flares
3
PubMed Central. Non‐steroidal anti‐inflammatory drugs for acute gout
4
PubMed Central. Effectiveness and safety of anakinra in gouty arthritis: A case series and review of the literature
5
PubMed. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial
6
BMJ Journals. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study
7
The Open Urology & Nephrology Journal. Management of Acute and Chronic Gout – The Nephrology Perspective
8
PubMed. Febuxostat compared with allopurinol in patients with hyperuricemia and gout
9
PubMed. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study
10
JAMA. Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment: Two Randomized Controlled Trials
11
PubMed Central. When underlying biology threatens the randomization principle – initial gout flares of urate-lowering therapy
12
Rheumatology. Prophylaxis for acute gout flares after initiation of urate-lowering therapy
13
PubMed. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy
14
Annals of the Rheumatic Diseases. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout
15
Exploration of Musculoskeletal Diseases. Safety and efficacy of gout treatments in people with renal impairment
16
The Lancet Rheumatology. Association between baseline serum urate concentration or crystal burden and time to flare resolution
17
PubMed. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy
18
PubMed Central. Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study